Use of a Decision Tree and Omics Data May Help Improve Survival Rates in Advanced NSCLC
Researchers suggest a less-is-more approach may be better than relying on “big data” when deciding on treatment at point of care.
Researchers suggest a less-is-more approach may be better than relying on “big data” when deciding on treatment at point of care.
Researchers at a single center in New York City reported on the various factors associated with poor outcomes after infection with SARS-CoV-2.
Initial data from a phase 1b trial shows encouraging results.
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
A risk signature is not constant in a given patient over time—it is subject to change depending on a variety of factors.
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis?
Researchers determined that gPALB2 may be a promising biomarker for talazoparib response.
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.